|
2020 Journal Article β-lactam antibiotic versus combined β-lactam antibiotic and single-daily dosing regimens of aminoglycosides for the treatment of serious infections: a meta-analysisHeffernan, Aaron James, Sime, Fekade Bruck, Sun, Jing, Lipman, Jeffrey, Kumar, Anand, Andrews, Katherine, Ellwood, David, Grimwood, Keith and Roberts, Jason (2020). β-lactam antibiotic versus combined β-lactam antibiotic and single-daily dosing regimens of aminoglycosides for the treatment of serious infections: a meta-analysis. International Journal of Antimicrobial Agents, 55 (3) 105839, 105839. doi: 10.1016/j.ijantimicag.2019.10.020 |
|
2020 Conference Publication Pharmacodynamic evaluation of intermittent versus prolonged infusion dosing regimens of piperacillin/tazobactam in a hollow-fiber infection model against two susceptible Klebsiella pneumoniae clinical isolatesSumi, Chandra Datta, B.Sime, Fekade, Heffernan, Aaron J., Naicker, Saiyuri, Islam, Kamrul, Cottrell, Kyra, Harris, Patrick N.A. and Roberts, Jason A. (2020). Pharmacodynamic evaluation of intermittent versus prolonged infusion dosing regimens of piperacillin/tazobactam in a hollow-fiber infection model against two susceptible Klebsiella pneumoniae clinical isolates. Federation of Infection Societies Conference 2019, Edinburgh, United Kingdom, 11-14 November 2019. London, United Kingdom: The Microbiology Society. doi: 10.1099/acmi.fis2019.po0103 |
|
2020 Journal Article A population pharmacokinetic model-guided evaluation of ceftolozane/tazobactam dosing in critically ill patients undergoing continuous venovenous hemodiafiltrationSime, Fekade B., Lassig-Smith, Melissa, Starr, Therese, Stuart, Janine, Pandey, Saurabh, Parker, Suzanne L., Wallis, Steven C., Lipman, Jeffrey and Roberts, Jason A. (2020). A population pharmacokinetic model-guided evaluation of ceftolozane/tazobactam dosing in critically ill patients undergoing continuous venovenous hemodiafiltration. Antimicrobial Agents and Chemotherapy, 64 (1) e01655. doi: 10.1128/aac.01655-19 |
|
2019 Journal Article Ceftolozane–tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability studyRaby, Edward, Naicker, Saiyuri, Sime, Fekade Bruck, Manning, Laurens, Wallis, Steven C., Pandey, Saurabh and Roberts, Jason A. (2019). Ceftolozane–tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study. European Journal of Hospital Pharmacy, 27 (e1) e19002093, e84-e86. doi: 10.1136/ejhpharm-2019-002093 |
|
2019 Journal Article A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic studyParker, Suzanne L., Pandey, Saurabh, Sime, Fekade B., Lipman, Jeffrey, Roberts, Jason A. and Wallis, Steven C. (2019). A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study. Analytical and Bioanalytical Chemistry, 411 (29), 7831-7840. doi: 10.1007/s00216-019-02184-4 |
|
2019 Other Outputs Development of population and Bayesian models for applied use in patients receiving cefepimeLiu, Jiajun, Neely, Michael, Lipman, Jeffrey, Sime, Fekade, Roberts, Jason, Kiel, Patrick J, Avedissian, Sean N., Rhodes, Nathaniel J. and Scheetz, Marc H. (2019). Development of population and Bayesian models for applied use in patients receiving cefepime. doi: 10.1101/19009647 |
|
2019 Journal Article The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysisMohd Sazlly, Lim S, Zainal Abidin, A., Liew, S.M., Roberts, J.A. and Sime, FB (2019). The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis. Journal of Infection, 79 (6), 593-600. doi: 10.1016/j.jinf.2019.09.012 |
|
2019 Journal Article Population pharmacokinetics of unbound ceftolozane and tazobactam in critically ill patients without renal dysfunctionSime, Fekade B., Lassig-Smith, Melissa, Starr, Therese, Stuart, Janine, Pandey, Saurabh, Parker, Suzanne L., Wallis, Steven C., Lipman, Jeffrey and Roberts, Jason A. (2019). Population pharmacokinetics of unbound ceftolozane and tazobactam in critically ill patients without renal dysfunction. Antimicrobial Agents and Chemotherapy, 63 (10) e01265-19. doi: 10.1128/aac.01265-19 |
|
2019 Journal Article What antibiotic exposures are required to suppress the emergence of resistance for gram‑negative bacteria? A systematic reviewSumi, Chandra Datta, Heffernan, Aaron J., Lipman, Jeffery, Roberts, Jason A. and Sime, Fekade B. (2019). What antibiotic exposures are required to suppress the emergence of resistance for gram‑negative bacteria? A systematic review. Clinical Pharmacokinetics, 58 (11), 1407-1443. doi: 10.1007/s40262-019-00791-z |
|
2019 Journal Article Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patientsSime, Fekade B., Byrn, Catherine J., Parker, Suzanne, Stuart, Janine, Butler, Jenie, Starr, Therese, Pandey, Saurabh, Wallis, Steven C., Lipman, Jeffery and Roberts, Jason A. (2019). Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. Critical Care, 23 (1) 205, 205. doi: 10.1186/s13054-019-2483-9 |
|
2019 Journal Article Multidrug-resistant Acinetobacter baumannii infections: current evidence on treatment options and role of PK/PD in dose optimizationLim, Sazlyna Mohd Sazlly, Sime, Fekade Bruck and Roberts, Jason (2019). Multidrug-resistant Acinetobacter baumannii infections: current evidence on treatment options and role of PK/PD in dose optimization. International Journal of Antimicrobial Agents, 53 (6), 726-745. doi: 10.1016/j.ijantimicag.2019.02.016 |
|
2019 Journal Article Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?Heffernan, A. J., Germano, A., Sime, F. B., Roberts, Jason A. and Kimura, E. (2019). Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?. European Journal of Clinical Pharmacology, 75 (9), 1219-1226. doi: 10.1007/s00228-019-02694-1 |
|
2019 Journal Article Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by gram-negative bacilli: a systematic reviewHeffernan, Aaron J., Sime, Fekade B., Lipman, Jeffrey, Dhanani, Jayesh, Andrews, Katherine, Ellwood, David, Grimwood, Keith and Roberts, Jason A. (2019). Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by gram-negative bacilli: a systematic review. International Journal of Antimicrobial Agents, 53 (3), 234-245. doi: 10.1016/j.ijantimicag.2018.11.011 |
|
2019 Journal Article Solid nanoparticles for oral antimicrobial drug delivery: a reviewRaza, Aun, Sime, Fekade Bruck, Cabot, Peter J., Maqbool, Faheem, Roberts, Jason A. and Falconer, James Robert (2019). Solid nanoparticles for oral antimicrobial drug delivery: a review. Drug Discovery Today, 24 (3), 858-866. doi: 10.1016/j.drudis.2019.01.004 |
|
2018 Journal Article How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patientsHeffernan, Aaron J., Sime, Fekade B., Taccone, Fabio S. and Roberts, Jason A. (2018). How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients. Current Opinion in Infectious Diseases, 31 (6), 1-565. doi: 10.1097/QCO.0000000000000494 |
|
2018 Journal Article A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminemia receiving continuous venovenous hemodiafiltrationSime, Fekade B., Stuart, Janine, Butler, Jenie, Starr, Therese, Wallis, Steven C., Pandey, Saurabh, Lipman, Jeffrey and Roberts, Jason A. (2018). A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminemia receiving continuous venovenous hemodiafiltration. International Journal of Antimicrobial Agents, 52 (4), 506-509. doi: 10.1016/j.ijantimicag.2018.07.008 |
|
2018 Journal Article Ex vivo characterisation of effects of renal replacement therapy modalities and settings on pharmacokinetics of meropenem and vaborbactamSime, Fekade B., Pandey, Saurabh, Karamujic, Nermin, Parker, Suzanne, Alexander, Elizabeth, Loutit, Jeffery, Durso, Stephanie, Griffith, David, Lipman, Jeffrey, Wallis, Steven C. and Roberts, Jason A. (2018). Ex vivo characterisation of effects of renal replacement therapy modalities and settings on pharmacokinetics of meropenem and vaborbactam. Antimicrobial Agents and Chemotherapy, 62 (10) e01306, AAC.01306-18. doi: 10.1128/AAC.01306-18 |
|
2018 Journal Article Pharmacokinetics of intravenous posaconazole in critically ill patientsSime, Fekade B., Stuart, Janine, Butler, Jenie, Starr, Therese, Wallis, Steven C., Pandey, Saurabh, Lipman, Jeffrey and Roberts, Jason A. (2018). Pharmacokinetics of intravenous posaconazole in critically ill patients. Antimicrobial Agents and Chemotherapy, 62 (6) e00242-18, e00242-18. doi: 10.1128/AAC.00242-18 |
|
2018 Journal Article Individualising therapy to minimize bacterial multidrug resistanceHeffernan, A. J., Sime, F. B., Lipman, J. and Roberts, J. A. (2018). Individualising therapy to minimize bacterial multidrug resistance. Drugs, 78 (6), 621-641. doi: 10.1007/s40265-018-0891-9 |
|
2018 Journal Article Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coliBergen, Phillip J., Bulitta, Jürgen B., Sime, Fekade B., Lipman, Jeffrey, McGregor, Megan J., Millen, Nada, Paterson, David L., Kirkpatrick, Carl M. J., Roberts, Jason A. and Landersdorfer, Cornelia B. (2018). Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli. Diagnostic Microbiology and Infectious Disease, 91 (1), 69-76. doi: 10.1016/j.diagmicrobio.2017.12.019 |
